Lee Dunlap

Lee Dunlap is an accomplished medicinal chemist with extensive experience in both research and advisory roles. Currently serving as an Advisor at Eli Lilly and Company since October 2025, Dunlap previously held the position of Scientist I at SiteOne Therapeutics, Inc. from January 2023 to October 2025. Prior experience includes a role as a Postdoctoral Researcher at the University of California, Davis, where work focused on the total synthesis of novel psychedelic analogs and preclinical evaluation of lead compounds. As a Chemistry Graduate Student at UC Davis from August 2016 to April 2022, Dunlap contributed to the SAR of psychedelics and developed non-hallucinogenic analogs maintaining therapeutic efficacy. Educational achievements include a PhD in Medicinal Chemistry from the University of California, Davis, and a Bachelor's degree in Organic Chemistry from the University of Tennessee, Knoxville.